Clinical Trial Update: CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating induction with venetoclax and ibrutinib followed by ibrutinib and obinutuzumab in CLL patients with MRD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: CLL | Phase 2 | Status: ACTIVE_NOT_RECRUITING